Guangzhou Leinkangya Biopharmaceutical Technology

Guangzhou Leinkangya Biopharmaceutical Technology is a clinical-stage biotechnology company specializing in the development of Targeted Protein Degradation (TPD) therapies. As a subsidiary of Leinkang Biopharmaceutical, the company focuses on the discovery and optimization of Proteolysis-Targeting Chimeras (PROTACs) to address challenging targets in oncology and immunology. Its lead candidate, LK-101, is an orally bioavailable androgen receptor degrader currently being evaluated in Phase 1 clinical trials for the treatment of metastatic castration-resistant prostate cancer. The company's pipeline also includes degraders targeting the estrogen receptor and STAT3, designed to overcome resistance to conventional small molecule inhibitors. Headquartered in Guangzhou, China, Leinkangya leverages its proprietary platform to advance a new generation of medicines for patients with unmet medical needs.